 Shares of First Wave BioPharma Inc. FWBI, -2.58 rocketed 46.6 on very heavy volume in premarket trading Tuesday, after the biopharmaceutical company said an independent data monitoring committee DMC recommended continued enrollment in a Phase 2 trial of its treatment FW-COV for COVID-19-related gastrointestinal GI infections. Trading volume spiked to 12.0 million shares ahead of the open, enough to make the stock the most actively traded in the premarket, and compared with the full-day average of about 1.4 million shares. 